89. Lymphangioleiomyomatosis
38 clinical trials,   42 drugs   (DrugBank: 19 drugs),   26 drug target genes,   134 drug target pathways
Searched query = "Lymphangioleiomyomatosis", "LAM"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT03062943 (ClinicalTrials.gov) | October 2016 | 7/10/2016 | A Study of Nintedanib for LymphAngioleioMyomatosis (LAM) | A Pilot Study of Nintedanib for LymphAngioleioMyomatosis (LAM) | Lymphangioleiomyomatosis | Drug: Nintedanib | IRCCS Multimedica | NULL | Recruiting | 18 Years | N/A | Female | 30 | Phase 2 | Italy |
2 | EUCTR2015-004919-20-IT (EUCTR) | 09/03/2016 | 11/08/2016 | A pilot study of nintedanib for lymphangioleiomyomatosis (LAM) | A pilot study of nintedanib for lymphangioleiomyomatosis (LAM) - A pilot study of nintedanib for lymphangioleiomyomatosis (LAM) | Female subjects affected by Llymphangioleiomyomatosis (LAM) MedDRA version: 19.0;Level: PT;Classification code 10049459;Term: Lymphangioleiomyomatosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Trade Name: Ofev | MULTIMEDICA S.P.A. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: no | 30 | Phase 3 | Italy |